STOCK TITAN

Microbot Medical Q3 revenue falls to $72K from $241K

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Microbot Medical Inc. reported third-quarter revenue of $72,000, down sequentially from $241,000 in the second quarter. The company attributed the decrease partly to summer seasonality, customer reorder timing and hospital Value Analysis Committee (VAC) processes. Gross margin was negative. Cost of goods sold rose 24% from Q2, largely due to an inventory write-down; under the FIFO inventory method, costs of systems sold primarily reflected earlier-manufactured units with higher production costs.

LIBERTY procedure utilization increased 44% from Q2, and customer accounts reached 12 from 10. Microbot said 100% of current customers that exhausted initial inventory reordered multiple systems. It ended Q3 with approximately $62 million in cash, cash equivalents and marketable securities. Manufacturing cost per unit continued to decline versus previous quarters. The company added two sales territories in Q3, reaching 10, and plans to expand to 12 by year-end 2026. It believes cost reductions and a planned second manufacturing line, if completed as planned, could support positive gross margin during 2027.

0 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 1 point

How the balance works

Positive

  • None.

Negative

  • Moderate pointThird-quarter revenue was $72,000, down from $241,000 in Q2.

Filing Explained

Microbot reports that, after Israeli regulatory approval, it entered a three-year exclusive agreement for Medtechnica to market and sell LIBERTY in Israel, establishing an exclusive distribution channel; initial orders are expected in the fourth quarter of 2026.

Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Third-quarter revenue $72,000 For the quarter ended September 30, 2026; $241,000 in the second quarter ended June 30, 2026
Cash, cash equivalents and marketable securities Approximately $62 million At the end of the third quarter
LIBERTY procedure utilization 44% increase Third quarter compared with the second quarter
Cost of goods sold 24% increase Third quarter compared with the second quarter
Customer accounts 12 accounts At the end of the third quarter, compared with 10 at the end of the second quarter
Sales territories 10 territories; planned expansion to 12 Reached 10 during the third quarter; planned expansion by the end of 2026
Value Analysis Committee medical
"hospital’s Value Analysis Committee (or “VAC”) process"
A value analysis committee is a group within a healthcare provider or hospital that evaluates medical products, devices, supplies, or procedures to judge their clinical effectiveness, safety, and cost implications before the organization buys or uses them. Think of it as a buying panel that balances quality and cost to decide which options deliver the best overall value. Its decisions matter to investors because they can affect a supplier’s sales, product adoption, and pricing in healthcare markets.
first-in, first-out (FIFO) financial
"under the Company’s first-in, first-out (FIFO) inventory method"
net realizable value financial
"measuring inventory at the lower of cost and net realizable value"
Net realizable value is the estimated amount a company expects to receive from selling an asset—typically inventory or a receivable—after subtracting any costs needed to finish, sell, or collect it. For investors it shows whether assets on the balance sheet are likely to convert into cash at their stated value, much like estimating how much you’d actually get from a garage sale after cleaning and listing fees; large gaps can signal future write-downs or weaker earnings.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What was MBOT's third-quarter revenue?

Microbot reported third-quarter revenue of $72,000, compared with $241,000 in the second quarter ended June 30, 2026. It attributed the sequential decrease partly to customer reorder timing, Q3 seasonality and hospital purchasing processes.

When does MBOT expect initial orders from its Israeli distributor?

Microbot expects initial orders during Q4 2026 under its three-year exclusive distribution agreement with Medtechnica Ltd. to market and sell LIBERTY in Israel. The agreement followed regulatory approval from the Israeli Ministry of Health’s AMAR Division.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0000883975 0000883975 2026-11-16 2026-11-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 16, 2026

 

MICROBOT MEDICAL INC.

(Exact name of registrant as specified in its charter)

 

Delaware   000-19871   94-3078125

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

175 Derby St., Bld. 27

Hingham, MA 02043

(Address of Principal Executive Offices) (Zip Code)

 

Registrant’s telephone number, including area code: (781) 875-3605

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.01 par value   MBOT   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging Growth Company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 7.01 Regulation FD Disclosure.

 

On November 16, 2026, Microbot Medical Inc. (the “Company”) disseminated a press release announcing that it has filed its Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2026, and providing highlights of the Company’s third quarter ended September 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing. By furnishing the information in this Current Report on Form 8-K and Exhibit 99.1, the Company is making no admission as to the materiality of any information in this Item 7.01 or Exhibit 99.1.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit

Number

  Description
     
99.1   Press Release dated November 16, 2026
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  MICROBOT MEDICAL INC.
   
  By: /s/ Harel Gadot
  Name: Harel Gadot
  Title: Chief Executive Officer, President and Chairman

 

Date: November 16, 2026

 

 

 

 

Exhibit 99.1

 

 

Microbot Medical® Files 10-Q and Highlights Key Third Quarter Operating Achievements

 

Company continues to expand commercial presence in the U.S. while it progresses international market entry and opportunities

 

Increased the number of health systems and hospital sites using LIBERTY, while utilization of the LIBERTY System rose 44% compared to the second quarter

 

HINGHAM, Mass., November 16, 2026 — Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, today announced that it has filed its Quarterly Report on Form 10-Q for the third quarter ended September 30, 2026, with the Securities and Exchange Commission.

 

The Company reported revenue of $72,000, a sequential decrease compared to revenue of $241,000 during the second quarter ended June 30, 2026. The revenue decrease in Q3 was due to a number of variables including timing of customer re-orders and the seasonality of Q3 (lower activity during summer months). In addition, taking into consideration that the Full Market Release commenced approximately 6 months ago, and that a hospital’s Value Analysis Committee (or “VAC”) process takes approximately 4-6 months, multiple potential new accounts are still in their VAC process. The Company believes that gaining widespread access to hospital systems through a VAC process could accelerate adoption of the LIBERTY System across healthcare systems with multiple hospitals over time.

 

The Company reports that 100% of current customers who exhausted their initial inventory have reordered multiple systems, reflecting high customer satisfaction consistent with a Company conducted survey.

 

During the third quarter, the Company experienced increased procedure utilization within existing accounts.

 

As anticipated, the Company reported a negative gross margin in the third quarter. Cost of goods sold increased by 24% from the second quarter, largely due to an inventory write-down recognized as a result of measuring inventory at the lower of cost and net realizable value. In addition, under the Company’s first-in, first-out (FIFO) inventory method, the cost of systems sold during the quarter primarily reflected units manufactured in earlier periods at higher production costs. While these factors adversely affected gross margin in the third quarter, the manufacturing cost per unit of systems produced during the quarter continued to decline compared to the previous quarters, reflecting improvements in manufacturing efficiency. The Company expects its ongoing cost reduction initiatives and the planned addition of a second manufacturing line, if completed as planned, to further reduce manufacturing costs and believes these measures could enable it to achieve a positive gross margin during 2027.

 

Other Third Quarter and Recent Highlights

 

  ● The Company ended the third quarter with cash, cash equivalents and marketable securities of approximately $62 million, enabling the Company to continue executing its commercial strategy in the U.S. and internationally.
  ● Utilization (number of procedures) of the LIBERTY Endovascular Robotic System in Q3 is up 44% compared to Q2.
  ● Academic center in North Carolina adopted the LIBERTY System, becoming the Company’s second health system in the state of North Carolina to use the system.
  ● The Company’s first West Coast customer, located in California, is also its first Office-Based Lab customer.
  ● The Company ended the third quarter with 12 customer accounts, compared to 10 customer accounts at the end of the second quarter. Additionally, the Company added two sales territories during the third quarter, expanding to ten, and plans to increase to 12 sales territories by the end of 2026.
  ● Customers have used LIBERTY in a variety of procedure types, including Prostatic Artery Embolization (PAE), Y-90 Radioembolization, Genicular Artery Embolization (GAE) and Uterine Artery Embolization (UAE), which the Company believes supports its positioning of the LIBERTY System as a platform for multiple peripheral intervention procedures.

 

 
 

 

  ● Following regulatory approval from the Israeli Ministry of Health’s AMAR Division, the Company entered into a three-year exclusive distribution agreement with Medtechnica Ltd. to market and sell the LIBERTY System in Israel. The Company currently expects to receive initial orders under the agreement during the fourth quarter of 2026.
  ● During and after the third quarter, the Company received new patents in the U.S., Japan, China and Canada. As of this press release, the Company held 44 issued patents and 49 pending patent applications.
  ● The Company successfully completed the ISO certificate surveillance audit.

 

“In less than six months since the full market release of the LIBERTY System, we are encouraged by the quality of customers we have added, and we believe their repeat purchases reflect their satisfaction with LIBERTY,” commented Harel Gadot, CEO, President and Chairman. “While revenue this quarter in part reflected the seasonality of the third quarter and the sales cycle process associated with the VAC, we believe the progress we made this year positions us for several potential milestones over the coming months in the U.S. and the international markets in which we operate.”

 

LIBERTY is the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, and it is designed for precise vascular navigation while aiming to reduce radiation exposure and physical strain.

 

About Microbot Medical

 

Microbot Medical Inc. (NASDAQ: MBOT) is a commercial stage medical device company focused on transforming endovascular procedures through advanced robotic technology. Microbot’s LIBERTY® Endovascular Robotic System is the first single-use, remotely operated robotic solution designed for precision, efficiency and safety. Backed by a strong intellectual property portfolio and a commitment to innovation, Microbot is driving the future of endovascular care.

 

Learn more at www.microbotmedical.com and connect on LinkedIn and X.

 

Safe Harbor

 

Statements relating to future financial and/or operating results, revenue, gross margin, cost reductions, manufacturing capacity, sales territory expansion, customer orders and re-orders, distributor orders, future adoption of products, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “contemplates,” “continues,” “could,” “forecasts,” “intends,” “may,” “might,” “possible,” “potential,” “predicts,” “projects,” “should,” “would,” “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) should also be considered to be forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially, including, without limitation, market conditions; risks inherent in the commercialization of the LIBERTY® Endovascular Robotic System, including the Company’s limited commercial history and revenue; the length and outcome of hospital Value Analysis Committee and other purchasing processes and the resulting variability in quarterly revenue; the Company’s ability to retain customers and obtain re-orders; the Company’s ability to reduce costs, complete its second manufacturing line and achieve positive gross margin; the Company’s ability to hire and retain sales personnel; the performance of distributors; competition; reimbursement and hospital capital budgets; the Company’s need for additional capital and its cash resources; risks in the development of future versions of or applications for the system; uncertainty in the results of regulatory pathways and regulatory approvals; uncertainty resulting from political, social and geopolitical conditions; disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran and other neighboring countries; and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical® can be found under the heading “Risk Factors” in Microbot Medical’s Annual Report on Form 10-K for the year ended December 31, 2025, its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 and other periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Forward-looking statements speak only as of the date of this press release, and readers are cautioned not to place undue reliance on them https://url.us.m.mimecastprotect.com/s/upukC9r3JzIm0GkQSEhvhqNQht?domain=sec.gov. Microbot Medical® disclaims any intent or obligation to update these forward-looking statements, except as required by law.

 

Contacts:

 

IR@microbotmedical.com

Media@microbotmedical.com

 

 

 

Filing Exhibits & Attachments

5 documents

Keep reading